Drug Profile
Dermatan sulfate - Choncept
Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Choncept
- Class Antithrombotics; Glycosaminoglycans; Small molecules
- Mechanism of Action Glycosaminoglycan stimulants; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Thrombosis
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Thrombosis in USA
- 28 Oct 2016 Dermatan sulfate - Choncept is available for licensing as of 28 Oct 2016. http://www.choncept.com/index.html (Choncept website, October 2016)
- 28 Oct 2016 Early research in Thrombosis in USA before October 2016 (Choncept website, October 2016)